Idiopathic recurrent pericarditis may be largely driven by interleukin 1 pathway: JAHA

UK: Researchers in a recently published study in the Journal of the American Heart Association have challenged the current concept of idiopathic recurrent pericarditis (IRP). Although, "idiopathic" means "arising spontaneously or from an obscure or unknown cause," which implies that the pathophysiology is not established, and the treatment should remain empirical.

In the study, the authors have proposed that idiopathic recurrent pericarditis may be largely driven by the well‐known interleukin‐1 pathway. They also found that corticosteroid dependence in IRP is tied to chronic noninflammatory pain. Together, this implies autoinflammation in IRP and supports reducing reliance on corticosteroids in its management.

Idiopathic recurrent pericarditis is an orphan disease that is associated with significant morbidity, partly driven by corticosteroid dependence. Colchicine, innate immune modulators, and anti‐interleukin‐1 agents, pioneered in monogenic autoinflammatory diseases, have demonstrated remarkable efficacy in trials. This suggests that autoinflammation may contribute to IRP.

Claire J. Peet, Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, and colleagues characterized the phenotype of patients with IRP and monogenic autoinflammatory diseases and establish whether autoinflammatory disease genes are associated with IRP.

For this purpose, the researchers retrospectively analyzed the medical records of patients with IRP (n=136) and monogenic autoinflammatory diseases (n=1910) attending a national center (London, UK) between 2000 and 2021. 4 genes (MEFV, MVK, NLRP3, TNFRSF1A) were examined by next‐generation sequencing in 128 patients with IRP. The frequency of rare deleterious variants was compared to controls obtained from the Genome Aggregation Database.